Ensign Peak Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $785K | Hold |
24,890
| – | – | ﹤0.01% | 1386 |
|
|
2025
Q1 | $815K | Hold |
24,890
| – | – | ﹤0.01% | 1363 |
|
|
2024
Q4 | $900K | Hold |
24,890
| – | – | ﹤0.01% | 1384 |
|
|
2024
Q3 | $776K | Hold |
24,890
| – | – | ﹤0.01% | 1460 |
|
|
2024
Q2 | $666K | Hold |
24,890
| – | – | ﹤0.01% | 1513 |
|
|
2024
Q1 | $849K | Sell |
24,890
-1,256
| -5% | -$42.8K | ﹤0.01% | 1422 |
|
|
2023
Q4 | $757K | Hold |
26,146
| – | – | ﹤0.01% | 1529 |
|
|
2023
Q3 | $721K | Hold |
26,146
| – | – | ﹤0.01% | 1435 |
|
|
2023
Q2 | $786K | Hold |
26,146
| – | – | ﹤0.01% | 1435 |
|
|
2023
Q1 | $947K | Hold |
26,146
| – | – | ﹤0.01% | 1284 |
|
|
2022
Q4 | $933K | Buy |
26,146
+6,800
| +35% | +$243K | ﹤0.01% | 1217 |
|
|
2022
Q3 | $655K | Hold |
19,346
| – | – | ﹤0.01% | 1318 |
|
|
2022
Q2 | $559K | Hold |
19,346
| – | – | ﹤0.01% | 1415 |
|
|
2022
Q1 | $625K | Hold |
19,346
| – | – | ﹤0.01% | 1457 |
|
|
2021
Q4 | $564K | Sell |
19,346
-30,740
| -61% | -$896K | ﹤0.01% | 1583 |
|
|
2021
Q3 | $1.34M | Hold |
50,086
| – | – | ﹤0.01% | 1311 |
|
|
2021
Q2 | $1.54M | Hold |
50,086
| – | – | ﹤0.01% | 1252 |
|
|
2021
Q1 | $1.31M | Hold |
50,086
| – | – | ﹤0.01% | 1311 |
|
|
2020
Q4 | $1.26M | Sell |
50,086
-2,400
| -5% | -$60.4K | ﹤0.01% | 1299 |
|
|
2020
Q3 | $1.09M | Hold |
52,486
| – | – | ﹤0.01% | 1272 |
|
|
2020
Q2 | $1.25M | Hold |
52,486
| – | – | ﹤0.01% | 1200 |
|
|
2020
Q1 | $944K | Buy |
52,486
+900
| +2% | +$16.2K | ﹤0.01% | 1192 |
|
|
2019
Q4 | $1.22M | Buy |
+51,586
| New | +$1.22M | ﹤0.01% | 1259 |
|